Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform.
Affiliation
Department of Oncology/Haematology, Kantonsspital, St. Gallen, SwitzerlandIssue Date
2016-07-19
Metadata
Show full item recordAbstract
Metformin is a safe, well-tolerated, inexpensive treatment that can be given in addition to current standard-of-care therapies for prostate cancer. Its use might mitigate the deleterious side effects of castration and exert an additional anticancer effect. It will be incorporated in the STAMPEDE trial platform in summer 2016. This will test its true utility as a repurposed treatment for men with high-risk locally advanced or metastatic prostate cancer at first presentation.Citation
Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform. 2016: Eur. Urol.Journal
European urologyDOI
10.1016/j.eururo.2016.07.015PubMed ID
27450106Type
ArticleLanguage
enISSN
1873-7560ae974a485f413a2113503eed53cd6c53
10.1016/j.eururo.2016.07.015
Scopus Count
Collections
Related articles
- A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
- Authors: Nobes JP, Langley SE, Klopper T, Russell-Jones D, Laing RW
- Issue date: 2012 May
- Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
- Authors: Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ
- Issue date: 2014 Jun 30
- Re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709-16.
- Authors: Bensimon L, Suissa S, Azoulay L
- Issue date: 2013 Aug
- Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.
- Authors: Richards KA, Liou JI, Cryns VL, Downs TM, Abel EJ, Jarrard DF
- Issue date: 2018 Dec
- Reply to Leah Bensimon, Samy Suissa, and Laurent Azoulay's letter to the editor re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709-16.
- Authors: Spratt DE, Zhang Z, Zelefsky MJ
- Issue date: 2013 Aug